Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection
Autore:
Tamalet, C; Pasquier, C; Yahi, N; Colson, P; Poizot-Martin, I; Lepeu, G; Gallais, H; Massip, P; Puel, J; Izopet, J;
Indirizzi:
Hop Enfants La Timone, Virol Lab, F-13385 Marseille 5, France Hop Enfants La Timone Marseille France 5 ab, F-13385 Marseille 5, France Hop Purpan, Virol Lab, Toulouse, France Hop Purpan Toulouse FranceHop Purpan, Virol Lab, Toulouse, France Hop Ste Marguerite, Hematol Serv, Marseille, France Hop Ste Marguerite Marseille France te, Hematol Serv, Marseille, France Hop Concept, Serv Malad Infect, Marseille, France Hop Concept Marseille France cept, Serv Malad Infect, Marseille, France Hop Purpan, Serv Malad Infect & Trop, Toulouse, France Hop Purpan Toulouse France , Serv Malad Infect & Trop, Toulouse, France
Titolo Testata:
JOURNAL OF MEDICAL VIROLOGY
fascicolo: 2, volume: 61, anno: 2000,
pagine: 181 - 186
SICI:
0146-6615(200006)61:2<181:PODRMA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; ZIDOVUDINE; INHIBITOR; PROTEASE; VIREMIA; TRANSMISSION; ADHERENCE; MUTATIONS;
Keywords:
primary HIV-1 infection; transmitted drug-resistant mutant; combination therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Tamalet, C Hop Enfants La Timone, Virol Lab, 264 Rue St Pierre, F-13385 Marseille 5, France Hop Enfants La Timone 264 Rue St Pierre Marseille France5 nce
Citazione:
C. Tamalet et al., "Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection", J MED VIROL, 61(2), 2000, pp. 181-186

Abstract

Baseline genotype resistance analysis was carried out in 48 adults with primary HIV-1 infection between 1995 and 1998 before starting early combination therapy. Seventeen percent (8/48) of the isolates displayed key mutations conferring resistance to reverse transcriptase (RT) inhibitors such as amino acid substitutions 215Y/F 15/48,10%), 70R (3/48, 6%), 184V (2%). Two percent (1/48) had a major mutation associated with resistance to protease inhibitors (D30N). Other mutations at positions 10, 15, 20, 33, 36, 46, 63, 71,77, 82, 93 of the protease gene were frequent (73%). Among the 46 patients who were given antiretroviral combination therapy and who responded durably to treatment after 6 and 12 months, there was no significant difference between those harboring RT muta nt strains (Group I) and those with wild-type isolates (Group II). No significant difference was found at months 6 and12 between the two groups in terms of CD4+ cell counts. These findings suggest that the presence of drug-resistant strains at the time of primary HIV-1 infection does not necessarily predict drug failure. Other factors, suchas adherence to treatment, tolerance and pharmacokinetics parameters are probably major determinants of virological response in patients with early therapeutic intervention. (C) 2000 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 04:37:57